Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd > You idiots that listened to the shorts are gonna regret it
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(127)
•••
Post by Photoman77on Nov 09, 2021 8:05pm
277 Views
Post# 34107585

You idiots that listened to the shorts are gonna regret it

You idiots that listened to the shorts are gonna regret itWhether you want to believe it or not, Aristotle is generating huge buzz, better than they aniticipated.

There has been huge amounts of shares being bought between Fidelity Investments and Dejardains Financial, even as the share price trickles down, they keep bying larger lots of shares on a daily basis. They have bought over 4 million shares over the last 3 months, ever since the Care deal closed and Aristotle was released for actual purchase in September 2021.

Noone putting down that king of money wthout some insight on to what is transpiring in the background at SZLS.

You will all regret buying into the fear the shorts are trying to convey here. Notice how hard they work day in and day out to keep that fear in the air??

Tripp drops a suttle hint with his comment:

and the introduction of Aristotle and AVRT are generating the interest we anticipated amongst patients, physicians and healthcare groups. It is an exciting time for us".

Don't let the shorts try and twist this around.

Get ready for pay day!

 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities